A Two-stage Simon Design Phase II Study for NOn-BRCA Metastatic BReast Cancer (MBC) Patients With Homologous Recombination Deficiency Treated With OLAparib Single Agent
Latest Information Update: 23 Feb 2023
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms NOBROLA
- 23 Mar 2022 Status changed from recruiting to discontinued.
- 19 Mar 2020 Planned primary completion date changed from 31 Jan 2020 to 31 Jul 2021.
- 13 Sep 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Jan 2020.